Tag: Manfred Lindinger
Food for Thought: Weekly Wrap-Up
Manfred Lindinger in Frankfurter Allgemeine Zeitung (FAZ) introduces a giant molecule the size of a virus. It is not a macromolecule – instead, it consists of just two rubidium atoms glued together by one electron.
Forget about “good” cholesterol, writes Nicola von Lutterotti, also in FAZ. Latest studies revealed that drug therapies to increase HDL failed to reduce the risk for cardiovascular events and did not prolong life.
Klaus Sievers in Die Welt explains how sewage plants can be used to produce electricity. The trick is done by microbial fuel cells populated by metal-reducing bacteria.
Garage biotech is approaching fast, writes Ted Greenwald in Forbes. He introduces OpenPCR, a $599 build-it-yourself PCR machine and PersonalPCR, a $149 2-tube PCR thermocycler by a company called Cofactor Bio. The DNA analysis is performed by Cofactor. Already, the machines have been used by high school students to identify tilapia fish sold as white tuna in a sushi restaurant.
The Economist features Ron DePinho, the new president of the MD Anderson Cancer Center in Houston, TX, a serial entrepreneur who us planning to use the results of the International Cancer Genome Consortium to develop new drugs against five cancers. The effort is financed by a $3 billion cancer-research fund created by the state of Texas and local philanthropists.
In the New York Times (NYT), Gina Kolata profiles Eric Lander, founding director of the Broad Institute of Harvard and the MIT, who excelled as a mathematician but then was attracted by fruit flies and nematodes so that he finally decided to become a geneticist.
Susanne Kutter introduces in Wirtschaftswoche the latest, indispensable winter outfit: gloves that allow for the handling of smartphone and camera touch screens.
Last not least, Hanna Wick in Neue Zürcher Zeitung (NZZ) introduces “Science Ink”, a book by US science writer Carl Zimmer which features tattoos worn by researchers and science enthusiastics, e. g. Schroedinger’s cat, a geological cross section or a piece of DNA.
Food for Thought: Weekly Wrap-Up
Solar cells can become cheap bulk ware, even for developing countries, writes Manfred Lindinger in Frankfurter Allgemeine Zeitung (FAZ). He introduces a technology for printing a sheet of zinc oxide, a polymer containing fullerenes and an electrode made from polymers on paper. The technology developed at Technical University Chemnitz can use ordinary printing machines and paper, and the resulting solar paper can be bended and folded. However, the efficiency is still very poor (1.3% at 5 V compared to 10 or more with conventional ones). Life span will amount to a few months. For other approaches to make cheaper solar cells, see this post.
Martina Lenzen-Schulte, also in FAZ, explains how measle viruses leave cells to enter the airway. Today it is known that they do not proliferate in the outer epithelium cells but in lymph nodes. The way back is facilitated by the membrane protein nectin-4, which acts as a transporter carrying the virus through epithelial cells. Lenzen-Schulte also reports that the effect may explain why cancer cells, which often overexpress nectin-4, are vulnerable to measle and other viruses. This might pave a way to develop new oncolytic viruses.
Ernst-Ludwig Winnacker, the nestor of the German biotechnology industry, makes the case for green biotechnology in the weekly Die Zeit. Winnacker criticizes the concept of coexistence that tries to avoid a blending of genetically modified and conventionally bred plants by defining a minimum distance between cultivated areas. In Germany, a farmer cultivating GMOs is liable for every case of cross-breeding, a provision that effectively prohibits GMO cultivation as there is a zero threshold for “contamination”. Winnacker also criticizes the strategy of patenting genetically modified plants instead of protecting them with the traditional plant variety rights that allow for exemptions for the further use of GMOs by breeders and farmers. Green biotechnology, he writes, has – at least in Europe – become the scapegoat for everything that is wrong with modern agriculture, from monoculture to declining biodiversity to the death of bees, although Europe is almost free from GM plants. As 25 years of research into the risk of green biotechnology have not been able to reveal any real danger, Winnacker proposes to amend the German law on genetic engineering and to simply omit the measures restricting the cultivation of GMOs.
Diabetics may soon be able to measure blood sugar without pricking, reports Der Spiegel. A new technology developed by researchers of John’s Hopkins University enables measuring of blood sugar in tear fluid.
In Wirtschaftswoche, Matthias Hohensee introduces US-based 23andme company which offers genetic testing at a rate of $99 plus a flat fee of $9 per month for access to the data. The company, which was criticized for exaggerating the benefits of personal genetic testing, also changed its business model and is now offering its records comprising the data of 125,000 people for research purposes, e.g. to find out why certain hereditary diseases display incomplete penetrance in different carriers of the respective genes.
Theres Lüthi in Neue Zürcher Zeitung (NZZ) reports on clinical studies by Roche and Novartis in people suffering from Down’s or fragile X syndrome in an attempt to improve cognitive abilities.
Alyson Krueger in Forbes reports on a talk on synthetic biology given by Andrew Hessel of Singularity University during the Technonomy 2011 conference. Hessel describes synthetic biology as computer-assisted genetic design that goes from an idea to printing DNA to ultimately booting DNA and forecasts it will render the task of engineering life as straightforward as programming software, or creating a vaccine as simple as Tweeting.
Alex Knapp, also in Forbes, describes a “cyborg yeast” designed by researchers from the University of California at San Francisco and ETH Zurich, Switzerland. In the yeast, the expression of a certain gene can be switched on and off by different shades of red light. The technique may lead to advances in the production of proteins by yeast cultures.
The Economist reports on the first computational pathologist which can can distinguish between grades of breast-cancer cells to provide a more accurate prognosis than a human pathologist can manage.
And finally, scientists found a single gene which can make you appear kinder, reports Catherine de Lange in New Scientist. In experiments conducted at the University of Toronto, people with the so-called GG version of the oxytocin receptor gene were judged to be kinder than those with GA or AA versions. Those with GG variations used significantly more non-verbal empathetic gestures in their storytelling such as smiling and nodding which made them appear kinder.
Food for Thought: Weekly Wrap-Up
In Frankfurter Allgemeine Zeitung (FAZ), Manfred Lindinger reports on progress in designing intelligent materials. Physicists of Technical University Hamburg-Harburg succeeded in designing gold- and platinum-based materials that can be switched between hard and brittle or soft and elastic, just by applying different voltages. The trick is done by etching pores and channels into the material which subsequently are filled with perchloric acid.
Martina Lenzen-Schulte, also in FAZ, deals with the surprising finding that a screening test for ovarian cancer increases the number cases detected but at the same time does not improve survival. The test based on the CA-125 tumor marker was investigated in the PLCO longitudinal analysis comprising more than 75,000 women aged between 55 and 74 years, who were diagnosed as cancer-free at the beginning of the study. Half of them was tested once a year with the CA-125 test. While more women were diagnosed with ovarian cancer in the CA-125 test group, the outcome did not improve – in part, because the test did not detect the cancer early enough. Moreover, it resulted in a high number of false positives, and these patients were put at unnecessary risk of bleeding, infections, colon injuries and blood loss due to attempts to confirm the diagnosis via biopsies.
In Forbes, Matthew Herper features an interview with David Urdal, the now retiring CSO of Dendreon, who pioneered Provenge, the prostate cancer vaccine approved by the FDA last year as the first anti-cancer vaccine ever. Urdal in detail explains why the company did not specify overall survival as primary endpoint but choose to follow every patient for three years instead. While the FDA first ok’ed the approach and the FDA advisory committee recommended approval in 2007, the FDA did not approve it: in the committee, cell therapists were in favor of Provenge while the oncologists had doubts. The drug was approved only after another study, the famous IMPACT study, had been finished. Urdal maintains that this turned out to be very positive for Provenge: the study revealed new insights about progression in asymptomatic patients and demonstrated that the method to measure disease progression just by counting the time to the next progression event was inadequate. Urdal states that the FDA may have been right to reject Provenge in the first place: “I think if you follow the sentiments within the clinical community I think there was a sense of, okay, if it’s approved I’d probably prescribe it, but geez, it’s a small study, overall survival wasn’t the primary endpoint, there wasn’t a sense of enthusiasm for it, and I think in the end of course the IMPACT study results came back and this completely vindicated the results from the earlier trials.”
William Pentland, also in Forbes, introduces a new battery architecture invented by the Massachusetts Institute of Technology MIT. The semi-solid flow cell basically runs on “sludge”, combining the structure of so-called flow batteries, where the electrolytes are replaced from outside once they are consumed with the favorable energy potential of lithium-ion batteries. Pentland says the new design may have the potential of a game-changer, in particular in combination with electric cars and smart grids.
Todd Woody, also in Forbes, describes buildings that clean up after itself via panels coated with titanium dioxide particles that serve as photocatalysts. Once illuminated by the sun, the particles start destroying dirt on the panel’s surface and, as a side effect, can also clear the surrounding air from nitrogen oxide. The company selling the panels claims they can cut a building’s maintenance costs by a third to half.
The Economist this week makes a case for using personalized medicine approaches in clinical trials earlier. In most cases, the Economist writes, oncologists “base their treatment on where in the body a tumour has sprung up, rather than on which molecular aberrations have caused it”, adding that the same is true for recruiting volunteers for clinical trials, in particular Phase I.
Drawing conclusions from this year’s ASCO (American Society of Clinical Oncology) meeting, the Economist argues it may be much better to match the genetic profiles of patients to the drug being tested, rather than looking for the organs affected. The magazine introduces a study by Apostolia-Maria Tsimberidou of the University of Texas’s MD Anderson Cancer Centre, in which the author selected volunteers with late-stage cancer across various organs whose tumors were caused by a single, known mutation. 175 volunteers were administered a targeted therapy in a low-dose, Phase I setting while 116 received traditional therapy. In the targeted therapy group, 29% responded, while in the untargeted therapy group there were only 5% responders.
Mark Brown in Wired reports on Harvard University researchers who created the first living laser, a human embryonic kidney cell that was genetically engineered to produce a visible laser beam. The cell producing green fluorescent protein was put between two mirrors and when the team ran pulses of blue light through the cell, it began to emit green light. When bouncing between the mirrors, certain wavelengths were preferentially amplified until a visible laser beam was created for a few nanoseconds. The cell was left unharmed. At present, researchers foresee applications in cell biology research.
Last not least, Herbert Renz-Polster in Der Spiegel this week answers crucial questions on why kids like jelly babies buth not salad and Brussels sprouts and how they can be made to eat healthy. The answer: it’s the evolution stupid! It is more advisable to eat fat in order to survive the next famine, to eat hastily (who knows when the next rival appears) and it is also wise to avoid eating the unknown (maybe it’s poison). The simple advice: be patient, keep offering the healthy stuff and play while having a meal. That way, kids even learn to like seal fat, whale blubber and roasted locusts.
Food for Thought: Weekly Wrap-Up
In Frankfurter Allgemeine Zeitung (FAZ), Manfred Lindinger takes up the issue whether nanotechnology poses danger to human health and the environment in an article and an interview with Jochen Flasbarth, president of the German Federal Environment Agency (Umweltbundesamt – UBA). Flasbarth points out that UBA’s nanotechnology study published last year, highlighting gaps in knowledge about potential health hazards, was misunderstood by the media and the public as a sweeping warning of all things nano. He also dismisses calls for introducing a label for products containing nanotechnology: “If there is no risk, we don’t need to put up a warning sign.”
Several German papers feature and discuss an ad-hoc statement on preimplantation diagnosis issued January 18 by the German National Academy of Sciences Leopoldina and Berlin-Brandenburgische Akademie der Wissenschaften. It was drafted by 13 eminent German academians from biology, medicine, law and philosophy & ethics, among them nobelist Christiane Nuesslein-Volhard. The statement calls for admission of PID under narrowly defined circumstances (high risk of serious monogenic disorder, chromosomal dysfunction, miscarriage or stillbirth). The parliament needs to to regulate PID after the German Federal Supreme Court last year ruled that Germany’s ban on PID was based on misinterpretation of the country’s Embryo Protection Law.
John Tierney in The New York Times provides new insights on people who underwent personal genetic testing to learn about their risk for conditions from obesity to cancer and Alzheimer’s. It is widespread belief among experts and politicians that personal DNA testing needs careful supervision and cannot be offered without expert guidance. The NYT introduces two studies – one follow-up study of about 2,000 people who had a genomewide scan by Navigenics and one representative sample of 1,500 people – and found that the medical field overestimates the level of psychological anxiety or trauma caused by the results and is way too paternalistic about the tests. One researcher is quoted by saying: “We should recognize that consumers might reasonably want the information for nonmedical reasons. People value it for its own sake, and because they feel more in control of their lives.”
Gardiner Harris reports that the Obama administration has become so concerned about the slowing pace of new drugs coming out of the pharma industry that it has decided to start a federal billion-dollar drug development center. The “National Center for Advancing Translational Sciences” will open in October this year and will beef up early research results by finding leads against new targets or even perform preclinical studies so that projects become attractive to the pharma industry. NIH director Francis S. Collins who is behind the idea, is quoted by NYT as saying: “I am a little frustrated to see how many of the discoveries that do look as though they have therapeutic implications are waiting for the pharmaceutical industry to follow through with them.” In a first step, more than $700 million in research projects from other NIH institutes will be brought together at the new center.
Gina Kolata reports on an FDA advisory committee recommending approval of a new brain scan that can detect the typical plaques in the brains of living Alzheimer disease patients. The test has been developed by Avid Radiopharmaceuticals, now a subsidiary of Eli Lilly (see akampioneer, June 24, 2010).
In the New Scientist, Anil Ananthaswamy features findings from Australian researchers suggesting that Parkinson’s disease, Multiple Sclerosis and maybe other, more common diseases such as rheumatoid arthritis or diabetes, might be cured by antibiotics and subsequent (re-)colonization of the colon with bacteria from healthy people. The hypothesis was derived from case studies of Parkinson’s patients treated for colon infections, in which the treatment also abated the Parkinson’s symptoms. The researchers from the Center of Digestive Diseases in New South Wales are now planning a pilot study in Parkinson’s patients. Already, neuroanatomists from German Ulm University have suggested in 2003 that Parkinson’s might be caused by a bug that breaks through the mucosal barrier of the GI tract and enters the central nervous system via the vagus nerve (Journal of Neural Transmission, DOI: 10.1007/s00702-002-0808-2).
Linda Geddes reports on how cytokines associated with inflammation can enter the brain under certain circumstances and cause depression. Unfortunately, the article fails to mention German biotech company Affectis which already has Cimicoxib, an anti-inflammatory COX-2 inhibitor, in Phase II trials for the treatment of depression, after researchers discovered that COX-2 inhibitors can alleviate depression.